Physician-initiated Medication Review in a Type 2 Diabetes Outpatient Clinic

NCT ID: NCT05501223

Last Updated: 2022-08-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-01

Study Completion Date

2022-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aiming to reduce polypharmacy in patients with type 2 diabetes by using physician-initiated medication reviews.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be randomised to either standard care(annual visit at outpatient clinic) or standard care plus an intervention. The intervention is a medication consultation of 30-60 minutes that consist of a medication review and increased cross-sectoral communication. Follow-up is 6 months. Primary outcome are number of medications used, secondary outcomes are health related quality of life and persistance of medication changes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polypharmacy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Standard care + medication review

Group Type OTHER

Medication review

Intervention Type OTHER

30-60 minutes extra consultation regarding the patients drugs

Standard care

Intervention Type OTHER

Standard care i.e. visit at the Dept. of Endocrinology.

Control

Standard care

Group Type OTHER

Standard care

Intervention Type OTHER

Standard care i.e. visit at the Dept. of Endocrinology.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medication review

30-60 minutes extra consultation regarding the patients drugs

Intervention Type OTHER

Standard care

Standard care i.e. visit at the Dept. of Endocrinology.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. DM2
2. 12 medications in the central prescription list

Exclusion Criteria

1. inability to give written consent (e.g., inability to understand the intervention or language barriers);
2. active cancer or palliative treatment;
3. admitted to the hospital.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bispebjerg Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Karl Sebastian Johansson

Dr., PhD student

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bispebjerg Hospital

Copenhagen, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Karl Sebastian Johansson, MD

Role: primary

+4538635604

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P-2020-1012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.